Hyderabad, Jun 27 (PTI) Natco Pharma Limited today said it got the final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for the generic version of Vidaza (Azacitidine for Injection, 100mg per Vial), single-Dose Vial. Also Read - US House of Representatives Passes Landmark Bill Legalising Marijuana in Federal Level

According to a statement issued by the drug maker, Natco and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future. Also Read - US Announces Reward of up to USD 5 Million For Information About 26/11 Mastermind

Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome (MDS). Also Read - Trump Skips G20 Summit on Pandemic Preparedness, Later Spotted at His Golf Course: Report

Vidaza generated total combined sales of USD 188 million for the twelve-month period ending April 2017, based on industry sales data.

Natco shares are trading at Rs 969.25 apiece on BSE at 14.30 hrs down 0.33 per cent over previous close.

This is published unedited from the PTI feed.